NCT03240211View on ClinicalTrials.gov

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 2, 2022

Primary Completion Date

July 24, 2025

Study Completion Date

May 25, 2026

Conditions
PTCLCTCL
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg IV

DRUG

Pralatrexate

Pralatrexate 20 or 30 mg/m2 IV push

DRUG

Decitabine

Decitabine 10 mg/m2

Trial Locations (2)

22911

University of Virginia, Charlottesville

15212-4722

Allegheny Health Network, Pittsburgh

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

lead

University of Virginia

OTHER